Encorafenib, also known as LGX-818, is an orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells.
Huang, Shenlin; Jin, Xianming; Liu, Zuosheng; Poon, Daniel; Tellew, John; Wan, Yongqin; Wang, Xing; Xie, Yongping. Preparation of sulfonamidophenylimidazolylpyrimidine derivatives and analogs for use as protein kinase inhibitors. Assignee IRM LLC, Bermuda; Novartis A.-G. WO 2011025927. (2011).
